TNF-α inhibitor reduces drug-resistance to anti-PD-1: A mathematical model

Area of Science:

• Immunotherapy
• Mathematical Oncology
• Cancer Drug Resistance

Background:

• Drug resistance is a major challenge in cancer therapy, leading to treatment failure and relapse in many patients.
• Anti-programmed death-1 (anti-PD-1) therapy, which boosts anti-cancer T cell activity, can be subject to resistance.
• Understanding and overcoming resistance mechanisms are critical for improving patient outcomes in oncology.

Purpose of the Study:

• To investigate the potential of combining anti-tumor necrosis factor-alpha (anti-TNF-α) with anti-PD-1 therapy to reduce drug resistance.
• To utilize a mathematical model to simulate and optimize the efficacy of this combination therapy.
• To identify the most effective treatment schedule for combined anti-PD-1 and anti-TNF-α administration.

Main Methods:

• Development and application of a mathematical model based on experimental melanoma data.
• Simulation of combination therapy efficacy across various drug doses, initial tumor volumes, and treatment schedules.
• Analysis of treatment outcomes to determine optimal therapeutic strategies.

Main Results:

• Mathematical modeling demonstrates that combining anti-TNF-α with anti-PD-1 therapy can significantly reduce resistance to anti-PD-1.
• Simulations indicate that the efficacy of the combined therapy is dependent on dose, initial tumor size, and administration schedule.
• The most effective schedule identified involves injecting anti-TNF-α one week after anti-PD-1 within a 3-week treatment cycle.

Conclusions:

• Combination therapy with anti-PD-1 and anti-TNF-α shows promise in overcoming drug resistance in experimental melanoma.
• Optimizing the treatment schedule is crucial for maximizing the therapeutic benefit of this combined approach.
• The findings support further investigation into this combination therapy and its scheduling for clinical application in cancer treatment.